Analyst Price Target is $3.50
▼ -78.47% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Cadrenal Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a -78.47% upside from the last price of $16.26.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Cadrenal Therapeutics. This Buy consensus rating has held steady for over two years.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Read More